Il-6 binding molecules
US-2024158492-A1 · May 16, 2024 · US
Agents for use in the treatment of retinal inflammation
US10519232B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10519232-B2 |
| Application number | US-201515111986-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 22, 2015 |
| Priority date | Jan 22, 2014 |
| Publication date | Dec 31, 2019 |
| Grant date | Dec 31, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating retinal inflammation in a subject in need thereof, comprising administering to the subject an IL-6 inhibitor as an active ingredient, wherein said retinal inflammation comprises atrophic age-related macular degeneration (AMD) and retinitis pigmentosa and is not associated with neovascularization. 2. The method according to claim 1 , wherein said IL-6 inhibitor comprises (i) an antagonist of IL-6 activity or (ii) an antagonist of IL-6 receptor. 3. The method according to claim 1 , wherein said IL-6 inhibitor is administered intraocularly, or applied by topical ocular administration. 4. The method according to claim 1 , wherein said IL-6 inhibitor is in a concentration from 5 mg/mL to 500 mg/mL. 5. The method according to claim 1 , wherein said IL-6 inhibitor is an antibody recognizing IL-6, a soluble IL-6 receptor or an inhibitor of IL-6 translation. 6. The method according to claim 1 , wherein said IL-6 inhibitor is an antibody recognizing IL-6R or an IL-6R binding peptide. 7. The method according to claim 1 , wherein said IL-6 inhibitor is administered intraocularly by intravitreal injection. 8. The method according to claim 1 , wherein said IL-6 inhibitor is an antibody recognizing IL-6, a soluble IL-6 receptor or an antibody recognizing IL-6R.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Ophthalmic agents · CPC title
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title
against receptors for cytokines, lymphokines, interferons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10519232B2 cover?
- The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
- Who is the assignee on this patent?
- Univ Sorbonne, Centre Nat Rech Scient
- What technology area does this patent fall under?
- Primary CPC classification C07K16/248. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).